ELVNEnliven TherapeuticsNot started yet
A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
Chronic Myeloid Leukemia (CML) · Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive · Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 450 (planned)
- Started
- Dec 31, 2026
- Main results expected
- Dec 31, 2028
- Fully finished
- Jul 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI
Measured over: 24 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07905183 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC